X

ZANTAC INJECTION 25mg/ML

Product Information

Registration Status: Active

SIN02428P

ZANTAC INJECTION 25mg/ML is approved to be sold in Singapore with effective from 1988-12-21. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN02428P.

This product contains Ranitidine 25mg/ml in the form of INJECTION. It is approved for INTRAVENOUS, INTRAMUSCULAR use.

This product is manufactured by GLAXOSMITHKLINE MANUFACTURING SPA in ITALY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. [PubChem]

Indication

Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).

Mechanism of Action

The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.

Pharmacokinetics

Absorption
Approximately 50% bioavailability orally.
Distribution
* 1.4 L/kg * 1.76 L/kg [clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min)]
Metabolism
Hepatic. Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites, accounting for approximately 4%, 1%, and 1% of the dose, respectively.
Elimination

Clearance

* 29 mL/min [clinically significant renal function impairment] * 3 mL/min/Kg [neonatal patients]

Toxicity

LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.

Active Ingredient/Synonyms

RAN | Ranitidina | Ranitidinum | Ranitidine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!